Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 873-883 , November 2010

Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging

  • Jianquan Yang

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • ,
  • Haixun Guo

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • ,
  • Yubin Miao

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
    • Department of Dermatology, University of New Mexico, Albuquerque, NM 87131, USA
    • Corresponding Author InformationCorresponding author. 2502 Marble NE, MSC09 5360, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA. Tel.: +1 505 925 4437; fax: +1 505 272 6749.

Received 11 February 2010 ,Revised 7 May 2010 ,Accepted 17 May 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  2. Tatro JB, Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology. 1987;121:1900–1907
  3. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352–6358
  4. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mTechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  5. Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003;14:1177–1184
  6. Guo H, Shenoy N, Gershman BM, Yang J, Sklar LA, Miao Y. Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Nucl Med Biol. 2009;36:267–276
  7. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA. 1998;95:12814–12818
  8. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706
  9. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116–123
  10. Miao Y, Benwell K, Quinn TP. 99mTc-and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med. 2007;48:73–80
  11. Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, et al. 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008;49:823–829
  12. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αv β3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–1164
  13. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αv β3 for angiogenesis. Science. 1994;264:569–571
  14. Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, et al. Integrin alpha(v)beta(3) promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999;59:2724–2730
  15. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100
  16. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987;262:17703–17711
  17. Cheresh DA, Harper JR. Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit. J Biol Chem. 1987;262:1434–1437
  18. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res. 1990;50:6757–6764
  19. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled alpha(v)beta(3) integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071
  20. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892–902
  21. Li C, Wang W, Wu Q, Ke S, Houston J, Sevick-Muraca E, et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006;33:349–358
  22. Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, et al. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol. 2006;33:945–952
  23. Alves S, Correia JD, Gano L, Rold TL, Prasanphanich A, Haubner R, et al. In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). Bioconjug Chem. 2007;18:530–537
  24. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, et al. 68Ga-and 111In-labelled DOTA-RGD peptides for imaging of alpha(v)beta(3) integrin expression. Eur J Nucl Med Mol Imaging. 2008;35:1507–1515
  25. Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur J Nucl Med Mol Imaging. 2009;36:1469–1474
  26. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, et al. 64Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol. 2009;36:277–285
  27. Yang J, Guo H, Gallazzi F, Padilla RS, Berwick M, Miao Y. Evaluation of a novel RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem. 2009;20:1634–1642
  28. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707–1718
  29. Miao Y, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002;101:480–487
  30. Antunes P, Ginj M, Walter MA, Chen J, Reubi J, Maecke HR. Influence of different spacers on the biological profile of a DOTA-Somatostatin analogue. Bioconjug Chem. 2007;18:84–92

☆ Financial Support: This work was supported in part by the Southwest Melanoma SPORE Developmental Research Program, the DOD grant W81XWH-09-1-0105 and the NIH grant NM-INBRE P20RR016480. The image in this article was generated by the Keck-UNM Small Animal Imaging Resource established with funding from the W.M. Keck Foundation and the University of New Mexico Cancer Research and Treatment Center (NIH P30 CA118100).

PII: S0969-8051(10)00304-5

doi: 10.1016/j.nucmedbio.2010.05.006

Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 873-883 , November 2010

Article Tools

* Image Usage & Resolution